Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve Self

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|May 24, 2016
Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trialEdwin J Asturias, Ananda S Bandyopadhyay, Steve Self, et al.
Journal of Virology|December 20, 2013
Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesAllan deCamp, Peter Hraber, Robert T Bailer, et al.
Plos Pathogens|February 25, 2011
Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infectionGuido Ferrari, Bette Korber, Nilu Goonetilleke, et al.
The Lancet. Infectious Diseases|September 18, 2020
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trialGuy de Bruyn, David L Gordon, Theodore Steiner, et al.
Journal of Virology|February 17, 2017
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell ResponsesGerard Zurawski, Xiaoying Shen, Sandra Zurawski, et al.
Journal of Virology|November 16, 2018
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVACKaren V Kibler, Benedikt Asbach, Beatriz Perdiguero, et al.
Journal of Virology|October 17, 2019
Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"Karen V Kibler, Benedikt Asbach, Beatriz Perdiguero, et al.
Journal of Virology|June 5, 2015
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan Heeney, et al.
Plos One|April 15, 2016
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus MacaquesGerard Zurawski, Sandra Zurawski, Anne-Laure Flamar, et al.
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|May 24, 2016
Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trialEdwin J Asturias, Ananda S Bandyopadhyay, Steve Self, et al.
Journal of Virology|December 20, 2013
Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesAllan deCamp, Peter Hraber, Robert T Bailer, et al.
Plos Pathogens|February 25, 2011
Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infectionGuido Ferrari, Bette Korber, Nilu Goonetilleke, et al.
The Lancet. Infectious Diseases|September 18, 2020
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trialGuy de Bruyn, David L Gordon, Theodore Steiner, et al.
Journal of Virology|February 17, 2017
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell ResponsesGerard Zurawski, Xiaoying Shen, Sandra Zurawski, et al.
Journal of Virology|November 16, 2018
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVACKaren V Kibler, Benedikt Asbach, Beatriz Perdiguero, et al.
Journal of Virology|October 17, 2019
Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"Karen V Kibler, Benedikt Asbach, Beatriz Perdiguero, et al.
Journal of Virology|June 5, 2015
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan Heeney, et al.
Plos One|April 15, 2016
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus MacaquesGerard Zurawski, Sandra Zurawski, Anne-Laure Flamar, et al.
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
Pageof 5